-
Results for the first quarter 2014Oslo, Norway, 7 May 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the first quarter 2014.07 May 2014 -
FOCUS ON CERVICAL CANCERFDA approves first HPV test for primary cervical cancer screening28 Apr 2014
-
Focus on cervical cancerFDA advisory committee recommends Roche's HPV test for primary screening of cervical cancer.17 Mar 2014
-
Results for the fourth quarter and full year 2013Oslo, Norway, 27 February 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the fourth quarter and full year of 2013.27 Feb 2014
-
Regulatory Update on Cevira<sup>®</sup>27 Dec 2013
-
Photocure provides update on Visonac<sup>®</sup>Novel treatment for moderate to severe acne30 Oct 2013
-
Results for the third quarter and the first nine months 2013Oslo, Norway, 23 October 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the third quarter and first nine months of 2013.23 Oct 2013
-
Photocure Sponsors symposium at the 29th Congress of the Scandinavian Association of Urology and Urological NursesDiagnosis and management of non-muscle invasive bladder cancer: How to reach excellence!30 Sep 2013
-
Cevira® Phase 2b results presented at the annual Colposcopy meeting in Cologne, Germany22. Jahrestagung der Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie, 26.-28. September 201330 Sep 2013
-
Results for the second quarter and first half 2013Oslo, Norway, 22 August 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the second quarter and first half 2013.22 Aug 2013
-
Results for the first quarter 201325 Apr 2013
-
POSITIVE FINAL RESULTS OF PHASE 2B CEVIRA® STUDYResults demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.10 Apr 2013
-
Updated European Association of Urology Guidelines Strengthen Recommendation on Use of Hexvix®Recognizes Benefit of Hexvix in Reducing Recurrence Rate and Improving Time to Recurrence of Bladder Cancer03 Apr 2013
